Imaging brain tumors with FMISO in adults
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether a new imaging agent called FMISO can help see areas of low oxygen in brain tumors. It may help doctors better target treatment for gliomas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a brain tumor that is likely a glioma, and it is larger than 5 mL.
- You are generally well enough to be active (Karnofsky score >60 or ECOG <3).
- You have either already had treatment for your brain tumor, or you are willing to have standard care (radiation and temozolomide) after your biopsy or surgery.
- You are expected to live at least 6 more months.
- You do not have any metal implants or devices that are not safe for MRI.
- You do not have sickle cell disease, iron overload, or a history of severe allergic reactions to the agents used in this study.
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses special PET and MRI scans to map the activity and oxygen levels of brain tumors (gliomas). The results help doctors plan treatment that is more tailored to each patient.
This trial uses a special PET scan tracer called 18F-FMISO to see areas of low oxygen (hypoxia) in your tumor. The results may help doctors adjust your radiation plan to target those areas more precisely.
This early-phase study uses special PET/MRI scans to look at how a newly diagnosed high-grade glioma is changing under standard treatment. The goal is to see whether these scans can better assess the disease, which may help guide future care.
This study uses special PET scans (fluciclovine and FDG) and advanced MRI to create a detailed metabolic profile of glioblastoma. It may help doctors better understand your tumor before surgery.
This trial uses special MRI scans and a contrast agent to look at the immune environment of glioblastoma tumors. It may help doctors learn more about how the tumor responds to treatment.
This study looks at how brain tumors look on MRI and what biopsy tissue shows, using samples taken during planned surgery. It may help improve understanding of tumor biology and future treatment planning.
Hear when a new IDH Wild Type Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.